europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

CRISPR and Coronavirus

30/04/2020
BLOG
CRISPR and Coronavirus

CRISPR and the Coronavirus

A recent interview with Prof. Jennifer Doudna, a co-discoverer of the CRISPR-Cas9 system for genome editing, highlights potential applications of the technology to COVID-19.

The CRISPR (Clustered Regularly Interspaced Short Palindromic) genome editing system can be used to delete, insert, or alter any type of DNA/RNA, including that of humans, animals, plants, or microorganisms like bacteria. CRISPR is a highly versatile technique which has the potential to cure complex diseases at the genetic level efficiently.

In the interview with Amanpour and Company, Prof. Doudna discusses some of the recent efforts of her lab at UC Berkley. Together with more than 50 volunteer scientist and data management experts, she transformed part of UC Berkley's Innovative Genomics Institute into a testing facility for COVID-19. Prof. Doudna highlights the solidarity and collaboration of all parties involved:

"Many scientists, myself included […] really want to be contributing our expertise and we're not seeking to profit from it. We're working with university officials to see if we can put out […] a statement about how IP will be managed that comes out of this pandemic, [and] how discoveries can be made openly available".

Asked about the origins of CRISPR and its relation to virus fighting bacteria found naturally in organisms, Prof. Doudna said:

"CRISPR is an adapted immune system, it allows bacteria to detect viruses and protect themselves from future viruses […] a handful of scientists were studying [it and found] we could actually harness it as a technology for something quite different – that's genome editing. Reflecting on this during the pandemic, there's a fascinating parallel that bacteria have had to come up with creative ways to fight [viruses], and now here we are, humans, facing this challenge".

In the current coronavirus pandemic, CRISPR could be utilised in a number of ways. Employing CRISPR is possible as part of diagnostic tests: "enzymes can interact with nucleic acid, which is RNA or DNA, when they do that they turn on an activity […] that allows a big amplification of the signal".

These could, according to Prof. Doudna, be engineered to be carried out as part of at-home testing kits – not dissimilar to a pregnancy test. The benefit of this, aside from taking pressure off healthcare systems, is understanding who is infected and how to keep others safe.

Future applications of CRISPR could see the technology used to fight viruses directly. The lab of Dr. Stanley Qi, a colleague of Prof. Doudna at UC Berkley, has recently been looking at the possibility to develop a prophylactic response to corona and influenza viruses. This technique, based on the CRISPR-Cas9 system, is called PAC-MAN (Prophylactic Antiviral CRISPR in huMAN cells).

Prof. Doudna describes this as a clever approach, which could utilise CRISPR against the coronavirus to:

"literally go after […] only the viral RNA, and not RNAs that are present in normal cells".

However this approach is not immediately useful against the coronavirus. Although the technology shows promising results in lab settings, it is necessary to spend more time to achieve a stable delivery method which can appropriately access affected cells in lungs. Read here our blog on how soon we can respond to the coronavirus.

As an increasingly vital part of the biotechnology toolkit in medicine, the versatility of CRISPR continues to be promising. Such innovation and collaboration put the biotechnology industry at the forefront of providing solutions to the novel problems life throws our way!

Sources:
- https://www.youtube.com/watch?v=XzRMcO0Pw6U&mc_cid=339a84e023&mc_eid=c5d0e37744
- https://www.statnews.com/2020/03/30/crispr-pioneer-doudna-opens-lab-to-run-covid-19-tests/
- https://www.biorxiv.org/content/10.1101/2020.03.13.991307v1

Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies